PT3973987T - Combinação compreendendo um antagonista de il-4r, um corticoesteroide e um agonista beta2-adrenérgico de ação prolongada para tratar a asma - Google Patents
Combinação compreendendo um antagonista de il-4r, um corticoesteroide e um agonista beta2-adrenérgico de ação prolongada para tratar a asmaInfo
- Publication number
- PT3973987T PT3973987T PT211911201T PT21191120T PT3973987T PT 3973987 T PT3973987 T PT 3973987T PT 211911201 T PT211911201 T PT 211911201T PT 21191120 T PT21191120 T PT 21191120T PT 3973987 T PT3973987 T PT 3973987T
- Authority
- PT
- Portugal
- Prior art keywords
- antagonist
- administering
- treating
- methods
- preventing asthma
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 208000006673 asthma Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14306413 | 2014-09-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3973987T true PT3973987T (pt) | 2024-04-01 |
Family
ID=51570453
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT211911201T PT3973987T (pt) | 2014-09-15 | 2015-02-20 | Combinação compreendendo um antagonista de il-4r, um corticoesteroide e um agonista beta2-adrenérgico de ação prolongada para tratar a asma |
PT157089913T PT3107575T (pt) | 2014-09-15 | 2015-02-20 | Métodos de tratamento e prevenção de asma administrando um antagonista de il-4r |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT157089913T PT3107575T (pt) | 2014-09-15 | 2015-02-20 | Métodos de tratamento e prevenção de asma administrando um antagonista de il-4r |
Country Status (13)
Country | Link |
---|---|
US (3) | US10137193B2 (pt) |
EP (2) | EP3107575B1 (pt) |
JP (2) | JP6673840B2 (pt) |
KR (3) | KR102368450B1 (pt) |
CN (1) | CN106232140A (pt) |
AU (2) | AU2015218808B2 (pt) |
CA (1) | CA2940295A1 (pt) |
ES (1) | ES2897631T3 (pt) |
MX (2) | MX2016010854A (pt) |
PL (1) | PL3107575T3 (pt) |
PT (2) | PT3973987T (pt) |
RU (1) | RU2713406C2 (pt) |
WO (1) | WO2015127229A1 (pt) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
HUE064945T2 (hu) | 2012-08-21 | 2024-04-28 | Sanofi Biotechnology | Eljárások asztma kezelésére vagy megelõzésére IL-4R antagonista beadásával |
TWI755763B (zh) | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
CN111437387A (zh) | 2013-06-21 | 2020-07-24 | 赛诺菲生物技术公司 | 通过施用il-4r拮抗剂治疗鼻息肉症的方法 |
TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法 |
ES2858500T3 (es) | 2013-07-12 | 2021-09-30 | Knopp Biosciences Llc | Tratamiento de niveles elevados de eosinófilos y/o basófilos |
JP6673840B2 (ja) | 2014-02-21 | 2020-03-25 | サノフィ・バイオテクノロジー | Il−4r拮抗薬の投与により喘息を処置または予防するための方法 |
RU2704999C2 (ru) | 2014-02-28 | 2019-11-01 | Ридженерон Фармасьютикалз, Инк. | Способ лечения кожной инфекции путем введения антагониста il-4r |
KR20230158131A (ko) | 2014-11-14 | 2023-11-17 | 사노피 바이오테크놀로지 | Il-4r 길항제의 투여에 의한, 비용종을 동반한 만성 부비동염의 치료 방법 |
US20180056018A1 (en) * | 2016-08-31 | 2018-03-01 | Cephalon, Inc. | Inhalation Systems, Devices and Methods |
MX2019002344A (es) | 2016-09-01 | 2019-09-06 | Regeneron Pharma | Metodos de prevenir o tratar la alergia administrando un antagonista de il-4r. |
WO2018057776A1 (en) | 2016-09-22 | 2018-03-29 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor |
TWI784988B (zh) * | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
JP7321939B2 (ja) * | 2017-04-13 | 2023-08-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Il33及びil1rl1をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害 |
US11850283B2 (en) | 2017-06-27 | 2023-12-26 | Ohio State Innovation Foundation | Liponucleotide-based therapy for asthma |
EP3645009A4 (en) | 2017-06-27 | 2021-03-31 | The Ohio State Innovation Foundation | LIPONUCLEOTIDE THERAPY FOR COPD |
US11053309B2 (en) | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
EP3703818B1 (en) * | 2017-10-30 | 2023-11-01 | Sanofi Biotechnology | Il-4r antagonist for use in a method for treating or preventing asthma |
CA3099066A1 (en) | 2018-05-13 | 2019-11-21 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r inhibitor |
CN110872349A (zh) | 2018-09-04 | 2020-03-10 | 三生国健药业(上海)股份有限公司 | 结合人il-4r的抗体、其制备方法和用途 |
CN110746507B (zh) | 2018-12-25 | 2020-06-26 | 江苏荃信生物医药有限公司 | 抗人白介素4受体α单克隆抗体及其应用 |
US20230295312A1 (en) * | 2018-12-27 | 2023-09-21 | Akeso Biopharma, Inc | Antibody against human il-4ra and use thereof |
US11964016B2 (en) | 2019-03-21 | 2024-04-23 | Regeneron Pharmaceuticals, Inc. | Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy |
EP3962515A1 (en) * | 2019-05-01 | 2022-03-09 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-33 antagonist |
CA3147436A1 (en) * | 2019-07-16 | 2021-01-21 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
IL289613B2 (en) | 2019-08-05 | 2023-09-01 | Regeneron Pharma | IL-4R antagonist in combination with a scit regimen to increase immunotherapeutic efficacy and tolerability to a grass-specific allergen |
BR112022011098A2 (pt) * | 2019-12-09 | 2022-09-20 | Sanofi Biotechnology | Métodos para tratamento de distúrbios relacionados a il-4/il-13 digitalmente identificados |
EP3992974A1 (en) | 2020-11-02 | 2022-05-04 | Sanofi Biotechnology | Methods for treating digitally-identified il-4/il-13 related disorders |
CN116419746A (zh) * | 2020-08-05 | 2023-07-11 | 阿瑞泰治疗公司 | 右旋普拉克索用于治疗中度至重度哮喘的用途 |
KR20230082650A (ko) * | 2020-10-05 | 2023-06-08 | 사노피 바이오테크놀로지 | Il-4r 길항제를 투여하여 소아 대상체에서 천식을 치료하는 방법 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8808015D0 (en) | 1988-04-06 | 1988-05-05 | Ritter M A | Chemical compounds |
AU643427B2 (en) | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
US5714146A (en) | 1992-08-26 | 1998-02-03 | Board Of Regents Of The University Of Washington | IL-4 bone therapy |
EP0604693A1 (en) | 1992-12-29 | 1994-07-06 | Schering-Plough | Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same |
US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
DK2990420T3 (en) | 2000-05-26 | 2017-04-03 | Immunex Corp | USE OF INTERLEUKIN-4 RECEPTOR ANTIBODIES AND COMPOSITIONS THEREOF |
US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US8178098B2 (en) | 2001-04-03 | 2012-05-15 | National Jewish Health | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies |
CA2543982C (en) | 2003-11-07 | 2013-01-08 | Immunex Corporation | Antibodies that bind interleukin-4 receptor |
CA2550933A1 (en) | 2003-12-22 | 2005-07-14 | Amgen Inc. | Methods for identifying functional antibodies |
US7410781B2 (en) | 2004-02-27 | 2008-08-12 | Regeneron Pharmaceuticals, Inc. | IL-4/IL-13 specific polypeptides and therapeutic uses thereof |
US20090098142A1 (en) | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
TW200902555A (en) | 2005-01-03 | 2009-01-16 | Hoffmann La Roche | Antibodies against IL-13 receptor alpha 1 and uses thereof |
WO2007085815A2 (en) * | 2006-01-24 | 2007-08-02 | Domantis Limited | Ligands that bind il-4 and/or il-13 |
ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
ES2859825T3 (es) | 2006-10-02 | 2021-10-04 | Regeneron Pharma | Anticuerpos humanos con alta afinidad para el receptor IL-4 humano |
EP2022507A1 (en) | 2007-08-07 | 2009-02-11 | Universität Hamburg | Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy |
EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
DK2245064T3 (da) * | 2007-12-21 | 2014-10-27 | Medimmune Ltd | BINDINGSELEMENTER TIL INTERLEUKIN-4-RECEPTOR-ALFA (IL-4Ralfa) |
AU2009322556A1 (en) | 2008-12-01 | 2011-07-21 | Children's Hospital Medical Center | Methods of determining efficacy of glucocorticoid treatment of eosinophilic esophagitis |
EP2414520A2 (en) | 2009-03-31 | 2012-02-08 | Altair Therapeutics, Inc. | Methods of modulating an immune response to a viral infection |
WO2011156000A2 (en) * | 2010-06-07 | 2011-12-15 | Aerovance, Inc. | Use of il-4/il-13 antagonists to treat eosinophilic disorders |
EA028945B1 (ru) | 2010-10-06 | 2018-01-31 | Ридженерон Фармасьютикалз, Инк. | СТАБИЛЬНЫЕ ЖИДКИЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТИТЕЛА К АЛЬФА РЕЦЕПТОРУ ЧЕЛОВЕЧЕСКОГО ИНТЕРЛЕЙКИНА-4 (hIL-4Rα) |
JP2013544235A (ja) * | 2010-10-15 | 2013-12-12 | メドイミューン・リミテッド | 肺機能を改善する治療法 |
US20130052190A1 (en) | 2011-02-22 | 2013-02-28 | Oxagen Limited | CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions |
KR20140097217A (ko) * | 2011-11-01 | 2014-08-06 | 메디뮨 엘엘씨 | 급성 천식 악화의 빈도 및 중증도를 감소시키는 방법 |
HUE064945T2 (hu) | 2012-08-21 | 2024-04-28 | Sanofi Biotechnology | Eljárások asztma kezelésére vagy megelõzésére IL-4R antagonista beadásával |
PL2892927T3 (pl) | 2012-09-07 | 2018-11-30 | Regeneron Pharmaceuticals, Inc. | Sposoby leczenia atopowego zapalenia skóry przez podawanie antagonisty IL-4R |
CN111437387A (zh) | 2013-06-21 | 2020-07-24 | 赛诺菲生物技术公司 | 通过施用il-4r拮抗剂治疗鼻息肉症的方法 |
JP6673840B2 (ja) | 2014-02-21 | 2020-03-25 | サノフィ・バイオテクノロジー | Il−4r拮抗薬の投与により喘息を処置または予防するための方法 |
KR20230158131A (ko) | 2014-11-14 | 2023-11-17 | 사노피 바이오테크놀로지 | Il-4r 길항제의 투여에 의한, 비용종을 동반한 만성 부비동염의 치료 방법 |
EP3703818B1 (en) * | 2017-10-30 | 2023-11-01 | Sanofi Biotechnology | Il-4r antagonist for use in a method for treating or preventing asthma |
-
2015
- 2015-02-20 JP JP2016552595A patent/JP6673840B2/ja active Active
- 2015-02-20 WO PCT/US2015/016852 patent/WO2015127229A1/en active Application Filing
- 2015-02-20 KR KR1020167025669A patent/KR102368450B1/ko active IP Right Grant
- 2015-02-20 KR KR1020237041236A patent/KR20230167770A/ko active Application Filing
- 2015-02-20 CA CA2940295A patent/CA2940295A1/en active Pending
- 2015-02-20 ES ES15708991T patent/ES2897631T3/es active Active
- 2015-02-20 PL PL15708991T patent/PL3107575T3/pl unknown
- 2015-02-20 AU AU2015218808A patent/AU2015218808B2/en active Active
- 2015-02-20 EP EP15708991.3A patent/EP3107575B1/en active Active
- 2015-02-20 PT PT211911201T patent/PT3973987T/pt unknown
- 2015-02-20 US US14/627,728 patent/US10137193B2/en active Active
- 2015-02-20 KR KR1020227006120A patent/KR20220029765A/ko active Application Filing
- 2015-02-20 RU RU2016136364A patent/RU2713406C2/ru active
- 2015-02-20 PT PT157089913T patent/PT3107575T/pt unknown
- 2015-02-20 CN CN201580020533.9A patent/CN106232140A/zh active Pending
- 2015-02-20 MX MX2016010854A patent/MX2016010854A/es unknown
- 2015-02-20 EP EP21191120.1A patent/EP3973987B1/en active Active
-
2016
- 2016-08-19 MX MX2021008113A patent/MX2021008113A/es unknown
-
2018
- 2018-10-11 US US16/157,708 patent/US20190125865A1/en not_active Abandoned
-
2020
- 2020-11-26 AU AU2020277191A patent/AU2020277191B2/en active Active
-
2021
- 2021-03-29 US US17/215,604 patent/US20210322546A1/en active Pending
-
2023
- 2023-08-30 JP JP2023139455A patent/JP2023162343A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210322546A1 (en) | 2021-10-21 |
MX2016010854A (es) | 2017-01-05 |
KR20160113733A (ko) | 2016-09-30 |
CA2940295A1 (en) | 2015-08-27 |
EP3973987A1 (en) | 2022-03-30 |
PT3107575T (pt) | 2021-11-18 |
ES2897631T3 (es) | 2022-03-02 |
RU2016136364A3 (pt) | 2018-10-11 |
JP2023162343A (ja) | 2023-11-08 |
JP6673840B2 (ja) | 2020-03-25 |
JP2017507139A (ja) | 2017-03-16 |
AU2020277191A1 (en) | 2020-12-24 |
AU2015218808B2 (en) | 2020-09-24 |
KR20220029765A (ko) | 2022-03-08 |
RU2016136364A (ru) | 2018-03-22 |
PL3107575T3 (pl) | 2022-01-17 |
AU2020277191B2 (en) | 2024-05-16 |
US20190125865A1 (en) | 2019-05-02 |
RU2713406C2 (ru) | 2020-02-05 |
US10137193B2 (en) | 2018-11-27 |
WO2015127229A1 (en) | 2015-08-27 |
US20150246119A1 (en) | 2015-09-03 |
EP3107575A1 (en) | 2016-12-28 |
KR102368450B1 (ko) | 2022-02-28 |
AU2015218808A1 (en) | 2016-09-22 |
KR20230167770A (ko) | 2023-12-11 |
EP3973987B1 (en) | 2024-01-10 |
CN106232140A (zh) | 2016-12-14 |
EP3107575B1 (en) | 2021-09-01 |
MX2021008113A (es) | 2021-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL274134A (en) | Methods of treating or preventing asthma by administering an IL-4R agonist | |
PL3107575T3 (pl) | Sposoby leczenia lub zapobiegania astmie przez podawanie antagonisty IL-4R | |
HRP20181963T1 (hr) | Postupci za liječenje ili sprječavanje astme primjenom antagonista il-4r | |
HK1246714A1 (zh) | 用於神經調節的裝置和方法 | |
IL279627A (en) | A method for treating depression | |
PT3110848T (pt) | Métodos para tratamento de infeção cutânea por administração de um antagonista do il-4r | |
GB2524293B (en) | An inhaler | |
SG11201703980YA (en) | Respiratory gas therapy | |
GB201404942D0 (en) | An inhaler | |
GB201404945D0 (en) | An inhaler | |
ZA201700416B (en) | Methods for treating or preventing ophthalmological conditions | |
HK1215864A1 (zh) | 用於埋線療法的套管 | |
SG11201609350XA (en) | Methods for inhibiting necroptosis | |
GB201412130D0 (en) | An inhaler | |
HK1246206A1 (zh) | 用於治療青光眼的組合物和方法 | |
HK1223837A1 (zh) | 減少過劑量的組合物和方法 | |
SG11201700059WA (en) | Therapeutic agent for keratoconjunctive disorder | |
GB201409603D0 (en) | An inhalable medicament | |
IL247290A0 (en) | Methods of treating or preventing asthma by adding an il-4r antagonist | |
GB201401806D0 (en) | Novel methods for diagnosis and therapy | |
IL271284A (en) | Methods for treating or preventing asthma by administering an antagonist to -il-r4 | |
PT3703818T (pt) | Antagonista de il-4r para utilização num método para o tratamento ou prevenção de asma | |
IL246913B (en) | Methods for treating dermatitis by administering an antagonist to -il-4r | |
HU4417U (en) | Construction for stabilize rails | |
SG10201400823PA (en) | Therapeutic methods and compositions for treating diabetes |